Hidehito Horinouchi: Potential long-term clinical benefit from CheckMate 816
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X about a recent paper by Mark Awad et al. published in Journal of Clinical Oncology:
“CheckMate 816: Neoadjuvant Nivo and Ipi vs chemo in Resectable NSCLC.
Potential long-term clinical benefit.”
“Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer”
Authors: Mark Awad, Patrick Forde, Nicolas Girard, Nan Hu, Mariano Provencio Pulla et al.
More posts featuring Hidehito Horinouchi.
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital.
He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023